Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Other hematologic neoplasm 3Myeloid 1

Conditions

Breast Neoplasms 529Neoplasms 475Carcinoma, Non-Small-Cell Lung 394Prostatic Neoplasms 308Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 218Ovarian Neoplasms 200Leukemia, Myeloid, Acute 199Pancreatic Neoplasms 187Multiple Myeloma 175Squamous Cell Carcinoma of Head and Neck 134Recurrence 132Stomach Neoplasms 131Brain Neoplasms 126Carcinoma, Hepatocellular 125Melanoma 124Endometrial Neoplasms 122Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Hematologic Neoplasms 100Head and Neck Neoplasms 99Lymphoma 97Carcinoma, Renal Cell 97Urinary Bladder Neoplasms 93Sarcoma 90Glioma 88Lymphoma, Non-Hodgkin 82Rectal Neoplasms 81

Interventions

Cytarabine 3venetoclax 2Cladribine 2quizartinib 1pegylated granulocyte colony-stimulating factor 1Razoxane 1Mitoxantrone 1Idarubicin 1Gemtuzumab 1Dexrazoxane 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Sarcoma, Myeloid × 90 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡